Tilray (NASDAQ: TLRY) reported a loss of 32 cents per share in the second quarter, more than double what it reported last
Search Results for: HEXO
What’s in the offing for Village Farms (VFF) Q2 earnings?
Village Farms International (NASDAQ: VFF), a Canada-based vegetable producer that entered into cannabis space in 2017, will be reporting its second quarter
Earnings insights from Aphria’s fourth quarter 2019 conference call
After swinging to a profit on GAAP basis and reporting a rise in revenue for the fourth quarter of 2019, Aphria’s (NYSE:
Aphria stock jumps after reporting better-than-expected Q4 results
Aphria Inc. (NYSE: APHA TSX: APHA) reported fourth quarter 2019 results after the bell. Aphria stock surged about 20% in the extended
Cronos Group ropes in Mondelez executive to drive innovation in product development
Global cannabinoid firm, Cronos Group (NASDAQ: CRON) on Tuesday announced the appointment of Dr. Todd Abraham as its Chief Innovation Officer. He
Earnings: Canopy Growth posts big Q4 miss, but investors remain stoic
Canopy Growth (NYSE: CGC) reported a loss of CAD 0.98 per share on revenues of CAD 94.1 million in the fourth quarter,
What you need to know before buying Village Farms International stock
Most marijuana stocks have fared well over the past one-and-half-years. So if you have already picked up a few of them, well
Canopy Growth names Constellation Brands veteran as acting CFO
Image by Rex Medlen from Pixabay Shares of Canopy Growth Corporation (NYSE: CGC) gained over 2% on Tuesday after the cannabis giant
Kohl’s Corp disappoints in Q1, slashes outlook
Retail giant Kohl’s Corp (NYSE: KSS) saw its shares plunge 10% during the morning trade on Tuesday after reporting lower-than-expected first-quarter earnings
Tilray earnings preview: Investors need more than just production expansion
Though the marijuana industry has been seeing overall tremendous growth, one prominent name has been pulling it down – Tilray (NASDAQ: TLRY).
Cronos Group starts off fiscal 2019 with a profit in Q1
In the first quarter of 2019, Cronos Group (NASDAQ: CRON) more-than-doubled its revenues to C$6.5 million, primarily driven by the launch of the
Earnings preview: ‘Joint’ venture with Altria to help Cronos Group in Q1
Come Thursday and Cronos Group (NASDAQ: CRON) officially kicks off another season of cannabis stock earnings. The Toronto-based marijuana firm is scheduled
Earnings: Array BioPharma reports upbeat Q3 results
Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during pre-market trading
Earnings preview: Plug Power will be looking to maintain momentum
What a year it has been for Plug Power (NASDAQ: PLUG)! The stock has almost doubled since the start of this year
Gilead Sciences earnings preview: What to expect in Q1
Gilead Sciences (NASDAQ: GILD) has tested its investors enough lately. The stock has increased just 2.5% in the year-to-date period, while its
Amarin Corp tops the market in Q1 on Vascepa strength
Amarin Corporation (NASDAQ: AMRN) on Wednesday said its revenues soared 67% to $73.3 million, riding on the strong demand for its Vascepa
Apple tops Q2 estimates despite weak product sales
Apple (NASDAQ: AAPL) reported yet another quarter of disappointing product sales as it announced second-quarter earnings results on Tuesday, primarily hurt by
Transocean gains on top line beat in Q1
Offshore drilling company Transocean (NYSE: RIG) reported a wider-than-expected loss of 30 cents per share in the first quarter of 2019. Analysts
Altria shares edge down after Q1 earnings miss
Shares of Altria Group Inc. (NYSE: MO) fell 2.5% during pre-market trading on Thursday after the tobacco company reported an earnings miss.
eBay poised for another earnings beat in Q1
eBay (NASDAQ: EBAY) is scheduled to report first-quarter 2019 earnings results on Tuesday, April 23, after the closing bell. Analysts expect the
Marijuana vs US: Will Aurora Cannabis survive in the banned market?
In the US, marijuana has been slowly turning to be legal in certain states but it still remained banned at the federal